Atlas Trials

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

Clinical trial NCT07224399 · RECRUITING

Trial details

NCT number
NCT07224399
Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
HealhtyOverweight or Obesity
Start date
2025-10-09
Primary completion
2026-05-15
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.